Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 20 participants, all of whom completed the study. The trial was looking at how tumours responded to a combination of two chemotherapy drugs — gemcitabine and docetaxel — in this single group of participants. Tumour response was measured using standard criteria that classify each person's result into one of four categories: complete response (all signs of tumour disappear), partial response (tumour shrinks by 30% or more), stable disease (tumour neither shrinks enough to count as a response nor grows enough to count as progression), or progressive disease (tumour grows by 20% or more). The reported data shows that out of the 20 participants: 1 had a complete response, 4 had a partial response, 9 had stable disease, and 6 had progressive disease. The trial also tracked how long it took, on average, before the disease progressed or a participant died — a measure known as "median time to progression" (meaning the midpoint value across all participants). The reported data shows this figure was 3 months. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with epithelial ovarian cancer, confirmed by a lab test of tissue samples
- Your cancer has stopped responding to platinum-based chemotherapy, meaning it either got worse during that treatment or came back within 6 months of finishing it
- Your cancer can be measured or detected — this includes having a significantly elevated CA-125 blood marker (100 or above, confirmed on two separate tests at least 2 weeks apart), though having positive fluid cytology alone does not qualify
- You are 18 years of age or older
- You are reasonably active and able to care for yourself (confirm with trial site regarding the specific activity level required)
- Your blood counts, kidney function, and liver function meet certain minimum health levels (the trial site will check these through blood tests)
- You have fully recovered from any side effects caused by previous cancer treatments
- You are willing and able to sign a consent form agreeing to take part
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have previously been treated with the chemotherapy drugs gemcitabine or docetaxel
- You have an existing medical, mental health, or personal situation that would make receiving treatment difficult or unsafe (confirm with trial site)
- You have nerve damage or numbness in your hands or feet that is moderate or severe
- You have never previously been treated with platinum-based chemotherapy drugs (such as cisplatin or carboplatin)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Tumor Response Type: CR, PR, SD or PD
Other options
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.